
Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
She was the supermodel dubbed 'The Face' in the '80s. Joining OnlyFans in her 60s taught her a lot. - 2
The most effective method to Distinguish the Best Material Organization in Your Space - 3
NASA, in a rare move, cuts space station mission short after an astronaut's medical issue - 4
Famous Kitchen Finishing Styles For 2024 - 5
Steven Spielberg's 'Disclosure Day' trailer drops: What we know about the alien movie
Germany records first wolf bite on human since repopulation
Air India chief resigns 10 months after devastating Ahmedabad crash and amid mounting financial troubles
Gartex Texprocess India to showcase innovations across textile ecosystem
Lecturer who called Israel a terrorist state to remain Plaid Cymru candidate
Why haven’t humans been back to the moon in over 50 years?
Relive NASA's historic Artemis 2 launch to the moon in these stunning photos
Five killed in Israeli air strikes on tents near Khan Younis, medics say
4 Family SUVs: Joining Solace and Style
The most effective method to Apply Antiquated Ways of thinking in Current Brain science Practices













